about
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathyMonitoring of hemodialysis quality-of-care indicators: why is it important?Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria.Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients.Progression of renal fibrosis: the underestimated role of endothelial alterations.Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans.Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury.Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.Acute renal failure and Fanconi syndrome due to deferasirox.Williams-Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in calcium homeostasis?Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism.Nephroangiosclerosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: is NOTCH3 mutation the common culprit?Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.Notch3 is essential for regulation of the renal vascular tone.Reduced insulin secretion and nocturnal dipping of blood pressure are associated with a disturbed circadian pattern of urine excretion in metabolic syndromeGenetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritisDifferential circadian pattern of water and Na excretion rates in the metabolic syndrome
P50
Q27308793-B1867EA8-6830-4581-BF8A-71EDCCDC8723Q34738880-00407BFD-0EB4-4893-8416-87AFD86B25C1Q34927100-BB2DE996-32C8-4665-B760-39FB90F033E1Q36108948-5D6C7D71-C800-4EC7-A260-7A847F329C02Q38069231-0460DF6C-19AC-403A-8244-186FE41BD103Q38184587-D3B668B3-7AA5-46F8-9063-DCCB1ED498A8Q39159146-18EF2056-415D-4232-8035-1B23E3348A7BQ39313049-45196F88-98A6-40E2-A46F-9BB293610FFFQ40134922-DEC1DC21-6B51-4EE4-903B-A96996408AAAQ43064228-328E6DC3-1D28-4279-B511-CCBF4A869202Q44697605-8ACE0775-7ADA-4789-BB60-5CFB34DC94CBQ46023332-51850886-CBE4-4DCF-98B9-C663E25A5961Q51874697-3F6E47F4-8D10-43D8-924C-A30269F91AB6Q54367805-2B300443-C16C-4CC6-A5BD-CE63C0E6D76FQ54376139-9FA56CDD-9949-4496-9916-102A535E3443Q83631023-2D8FB792-6149-4976-83E9-FB4A70B99955Q84507166-2765FEBC-11B8-41F3-94F6-AB439822C071Q87869146-33ABAEB8-8C44-4A2B-AF0B-1793533FB702
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dominique Guerrot
@ast
Dominique Guerrot
@en
Dominique Guerrot
@es
Dominique Guerrot
@nl
Dominique Guerrot
@sl
type
label
Dominique Guerrot
@ast
Dominique Guerrot
@en
Dominique Guerrot
@es
Dominique Guerrot
@nl
Dominique Guerrot
@sl
prefLabel
Dominique Guerrot
@ast
Dominique Guerrot
@en
Dominique Guerrot
@es
Dominique Guerrot
@nl
Dominique Guerrot
@sl
P1053
J-3722-2014
P106
P31
P3829
P496
0000-0001-9562-530X